When Atopic Dermatitis is Difficult to Control

Price: FREE for members and non-members
Session recorded on January 23, 2020
Speaker: William E. Berger, MD, FACAAI
Viewers can earn credit by completing the post test questions.

Atopic dermatitis is the most common form of eczema affecting 18 million adults and 9.6 million children under 18 years of age in the United States. Many patients are not being treated adequately and this is having a severe impact on their quality of life.

This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.

There is no commercial support for this activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Physicians

Learning Objectives

Upon viewing the video recording, learners should be able to:
1.    Identify the most common triggers of atopic dermatitis (AD) symptoms
2.    Utilize appropriate strategies for patients with severe AD
3.    Improve control of AD and implement new treatment regimens

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a "commercial interest" as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.


Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

All identified conflicts of interest have been resolved.

Sally Schlosser, RN, Planner, Reviewer
Nothing to disclose

Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare

William E. Berger, MD, Speaker
Disclosures: Speaker/honorarium: Astra Zeneca, Boehringer Ingelheim, Optinose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.